Clinical staging and histopathological findings after radical hysterectomy in FIGO stage IIB cervical cancer

被引:0
作者
Mandic, A. [1 ]
Novakovic, P. [1 ]
Mihajlovic, O. [1 ]
Stojiljkovic, B. [1 ]
Rajovic, J. [1 ]
Davidovic, M. [1 ]
机构
[1] Inst Oncol Vojvodina, Clin Surg Oncol, Dept Gynecol Oncol, Sremska Kamenica 21204, Serbia
来源
JOURNAL OF BUON | 2008年 / 13卷 / 01期
关键词
cervical cancer; clinical stage; nodal disease; parametrial invasion; pathological stage; stage IIB;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Advanced cervical cancer still represents a major health care challenge in the developing world. According to standard protocols the treatment of choice for stage IIB cervical cancer is cisplatin-based chemoradiotherapy. However in some European countries, and especially in Japan, patients with stage IIB cervical cancer are generally treated with radical hysterectomy as initial treatment. The aim of this study was to compare clinical stage with pathological findings, and also to correlate any relationship between parametrial infiltration and nodal status. Patients and methods: From 199 7 to 2006, 26 patients with FIGO stage IIB cervical cancer were radically operated (Piver class III operation). Preoperative clinical findings were compared with the pathological findings of the surgical material. The correlation between infiltration of the parametria and lymph node status was also examined. Fisher exact test was used to examine statistical significance. Results: The patients' median age was 48.3 years (range 36-61). The median number of removed lymph nodes was 16 (range 8-40). The histopathological types of cervical tumors were: squamous cell carcinoma 80%, adenosquamous carcinoma 15% and adenocarcinoma 5%. In 50% of the patients the parametria were infiltrated, suggesting that 50% of the patients were clinically overstaged. Positive lymph nodes were found in 69% of patients with positive parametria and 15% inpatients with negative parametria (p<0.05). Patients with positive lymph nodes received adjuvant chemoradiotherapy. Conclusion: Adequate preoperative staging such as clinical examination under anesthesia or nuclear magnetic resonance could help to exclude parametrial involvement in equivocal cases. Parametrial invasion presents an important risk factor for lymph nodes metastases.
引用
收藏
页码:51 / 54
页数:4
相关论文
共 50 条
  • [21] Revised (2018) FIGO stage IIB cervical cancer and prognostication in low-resource settings
    Lawal, Ishak Kayode
    Abdullahi, Habiba Ibrahim
    Obiokonkwo, Augustus Chiemeze
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2020, 149 (02) : 252 - 253
  • [22] FIGO stage IIB cervical cancer prognostication in low-resource settings
    Kehoe, Sean
    Bhatla, Neerja
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2020, 149 (02) : 254 - 254
  • [23] Sexual function after radical hysterectomy for early-stage cervical cancer
    Jongpipan, Juntana
    Charoenkwan, Kittipat
    [J]. JOURNAL OF SEXUAL MEDICINE, 2007, 4 (06) : 1659 - 1665
  • [24] Clinical and imaging findings in cervical cancer and their impact on FIGO and TNM staging - An analysis from the EMBRACE study
    Knoth, J.
    Poetter, R.
    Jurgenliemk-Schulz, I. M.
    Haie-Meder, C.
    Fokdal, L.
    Sturdza, A.
    Hoskin, P.
    Mahantshetty, U.
    Segedin, B.
    Bruheim, K.
    Wiebe, E.
    Rai, B.
    Cooper, R.
    van der Steen-Banasik, E.
    van Limbergen, E.
    Pieters, B. R.
    Sundset, M.
    Tan, L. T.
    Nout, R. A.
    Tanderup, K.
    Kirisits, C.
    Nesvacil, N.
    Lindegaard, J. C.
    Schmid, M. P.
    [J]. GYNECOLOGIC ONCOLOGY, 2020, 159 (01) : 136 - 141
  • [25] Analysis of Prognostic Factors Affecting the Outcome of Stage IB-IIB Cervical Cancer Treated by Radical Hysterectomy and Pelvic Lymphadenectomy
    Xia, Xi
    Xu, Hongbin
    Wang, Zhonghai
    Liu, Ronghua
    Hu, Ting
    Li, Shuang
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (06): : 604 - 608
  • [26] Survival impact of adjuvant concurrent chemoradiotherapy after radical hysterectomy in FIGO stage IIIC1 cervical adenocarcinoma
    Suzuki, Kazuhiro
    Nagao, Shoji
    Narita, Moyu
    Nakazawa, Hiroshi
    Shibutani, Takashi
    Yamamoto, Kasumi
    Jimi, Tomoatsu
    Yano, Hiroko
    Kitai, Miho
    Shiozaki, Takaya
    Matsuoka, Kazuko
    Yamaguchi, Satoshi
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (07) : 1322 - 1329
  • [27] Survival impact of adjuvant concurrent chemoradiotherapy after radical hysterectomy in FIGO stage IIIC1 cervical adenocarcinoma
    Kazuhiro Suzuki
    Shoji Nagao
    Moyu Narita
    Hiroshi Nakazawa
    Takashi Shibutani
    Kasumi Yamamoto
    Tomoatsu Jimi
    Hiroko Yano
    Miho Kitai
    Takaya Shiozaki
    Kazuko Matsuoka
    Satoshi Yamaguchi
    [J]. International Journal of Clinical Oncology, 2021, 26 : 1322 - 1329
  • [28] Radical hysterectomy after chemoradiation in FIGO stage III cervical cancer patients versus chemoradiation and brachytherapy: Complications and 3-years survival
    Fanfani, F.
    Vizza, E.
    Landoni, F.
    de Iaco, P.
    Ferrandina, G.
    Corrado, G.
    Gallotta, V.
    Gambacorta, M. A.
    Fagotti, A.
    Monterossi, G.
    Perrone, A. M.
    Lazzari, R.
    Colangione, S. P.
    Scambia, G.
    [J]. EJSO, 2016, 42 (10): : 1519 - 1525
  • [29] Preoperative nomogram for prediction of microscopic parametrial infiltration in patients with FIGO stage IB cervical cancer treated with radical hysterectomy
    Kong, Tae-Wook
    Kim, Jayoun
    Son, Joo-Hyuk
    Kang, Seong Woo
    Paek, Jiheum
    Chun, Mison
    Chang, Suk-Joon
    Ryu, Hee-Sug
    [J]. GYNECOLOGIC ONCOLOGY, 2016, 142 (01) : 109 - 114
  • [30] Primary Uterine Cervical Cancer: Correlation of Preoperative Magnetic Resonance Imaging and Clinical Staging (FIGO) with Histopathology Findings
    Kraljevic, Zdenko
    Viskovic, Klaudija
    Ledinsky, Mario
    Zadravec, Dijana
    Grbavac, Ivan
    Bilandzija, Marijana
    Soljaclc-Vranes, Hrvojka
    Kuna, Krunoslav
    Kasnic, Ksenija
    Krolo, Ivan
    [J]. COLLEGIUM ANTROPOLOGICUM, 2013, 37 (02) : 561 - 568